Recursion Pharmaceuticals, Inc. (RXRX) News
Follow Recursion Pharmaceuticals, Inc. (RXRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem
Altitude Lab to serve as anchor member of Portal at Woodbine Labs, bringing accelerator programming
EQUITY | Nov 05, 2026, 04:15 PM UTC
M
Recursion Pharmaceuticals Q3 Earnings Snapshot
Recursion Pharmaceuticals reported on Monday; the supplied report does not include results.
EQUITY | Nov 03, 2026, 04:37 AM UTC
M
Recursion Pharmaceuticals Extends Expected Cash Runway Into 2029
The company expects 2026 cash operating expenses below $375 million and 2027 expenses below $360 million.
EARNINGS | Nov 02, 2026, 10:20 PM UTC
M
Recursion Pharmaceuticals Reports Q3 EPS of USD -0.22
EARNINGS | Nov 02, 2026, 10:19 PM UTC
M
Recursion Reports Phase 2 REC-4881 Polyp Reductions
New analyses from the ongoing Phase 2 TUPELO trial showed polyp burden reductions across the GI tract, including larger, higher-risk polyps. Recursion anticipates starting a registrational trial in the second half of 202
EQUITY | Nov 02, 2026, 09:41 PM UTC
M
Recursion Reports Third-Quarter 2026 Revenue of $18.55M, EPS Loss of $0.22
Revenue rose from $5.18 million a year earlier, while net loss narrowed to $119.04 million from $162.25 million. Diluted EPS was a loss of $0.22, compared with $0.36 a year earlier.
EQUITY | Nov 02, 2026, 09:41 PM UTC
M
Recursion Pharmaceuticals Q3 Net Loss Narrows More Than Expected
EQUITY | Nov 02, 2026, 09:40 PM UTC
M
Recursion Pharmaceuticals Reports Q3 Operating Revenue of $18.055 Million
Q3 operating income was a loss. The headline reports operating revenue of $18.055 million versus an IBES estimate of $14.8 million.
EQUITY | Nov 02, 2026, 09:37 PM UTC
M
Recursion Reports Third-Quarter 2026 Results and Extends Cash Runway
Recursion also highlighted positive clinical data in REC-4881 and REC-1245, a Sanofi development-candidate option and the appointment of Fred Hassan as chair.
EQUITY | Nov 02, 2026, 09:32 PM UTC
M
Recursion Pharmaceuticals Phase 2 Shows 47% Median Polyp Burden Reduction
The Phase 2 update also says 85% of evaluable patients were below baseline after 12 weeks off treatment.
EQUITY | Nov 02, 2026, 09:30 PM UTC
M
Sanofi Selects Recursion Treatment for Inflammatory Diseases
Sanofi selected an experimental treatment developed through its multi-program research collaboration with Recursion Pharmaceuticals. Recursion shares rose more than 16% on Thursday; the update also coincided with a $200
EQUITY | Oct 15, 2026, 05:59 PM UTC
M
Recursion Prices 61.54 Million Shares at $3.25 in Public Offering
Recursion Pharmaceuticals agreed to sell 61,540,000 Class A shares at $3.25 each, expecting about $200 million in gross proceeds before fees. Closing is targeted for Oct. 16, 2026, subject to customary conditions.
EQUITY | Oct 15, 2026, 12:53 PM UTC
L
Sanofi Options Immunology Development Candidate From Recursion Collaboration
Recursion says Sanofi has exercised an option on a potential first-in-class immunology development candidate from their collaboration.
EQUITY | Oct 15, 2026, 12:45 PM UTC
L
Recursion Announces $200 Million Follow-On Offering, Clinical Data Updates and Partnership Milestone
Recursion announced a $200 million oversubscribed follow-on offering, clinical data updates and a partnership milestone.
EQUITY | Oct 15, 2026, 12:38 PM UTC
L
TEM RXRX - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
TEM RXRX - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
NEWS | Sep 21, 2026, 01:23 PM UTC
M
Recursion resets Tempus data pact and licenses TxFM RNA model in $12M deal
Recursion amended its long-term data collaboration with Tempus, extending the Master Agreement to a six-year term from a Nov. 3, 2023 start, removing its convenience termination right, and resetting Annual License Fees.
EQUITY | Sep 21, 2026, 01:14 PM UTC
H
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Recursion Pharmaceuticals (NASDAQ: RXRX ) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For
LIVE | Sep 17, 2026, 01:22 PM UTC
L
RXRX: AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones
The company has transformed into an end-to-end AI-driven drug discovery leader, achieving significant cost reductions and clinical progress with first-in-class assets like REC-4881 and REC-1245. Strategic partnerships wi
NEWS | Sep 15, 2026, 02:21 PM UTC
L
RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones
The conference highlighted a strategic transformation to an AI-driven, end-to-end drug discovery engine, with significant cost reductions and repeatable productivity. Key clinical assets like REC-4881 and REC-1245 are ad
NEWS | Sep 15, 2026, 01:36 PM UTC
L
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub
TEM shares now up over 23% PRME +17% RXRX +11% and DNA about 16%, extending gains all day in Precision Medicine, or Biomedical/genetics sub-areas which have all rallied behind the MRNA/MRK news today
EQUITY | Aug 19, 2026, 07:34 PM UTC
H
Cramer likes Vistra, Constellation Energy, Fastly after earnings
Jim Cramer said he likes Vistra and Constellation Energy on CNBC, called Fastly “back from the abyss,” and said Recursion, NextEra and Huntington Ingalls on the show.
EARNINGS | Aug 13, 2026, 12:00 PM UTC
L
RXRX - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program - Click
RXRX - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
EARNINGS | Aug 05, 2026, 10:30 AM UTC
L
RXRX Grants Inducement Awards
RXRX grants inducement awards
EQUITY | Jul 31, 2026, 08:30 PM UTC
L
RXRX - Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
RXRX - Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
EARNINGS | Jul 29, 2026, 12:30 PM UTC
L
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
2026-07-03 11:34:15 ET As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driv
EQUITY | Jul 03, 2026, 03:34 PM UTC
H
Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI
While corporate America is becoming more selective about using artificial intelligence as a rationale for acquisitions, Anthropic is making its biggest bet yet that AI will reshape scientific research. The AI startup on
MNA | Jul 01, 2026, 11:50 AM UTC